Docetaxel
- PDF / 169,451 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 35 Downloads / 163 Views
1 S
Neutropenia: case report A man in his late 60s [exact age at reaction onset not stated] developed neutropenia while receiving docetaxel for non-metastatic castration-resistant prostate cancer (nmCRPC). The man, who presented with a 3-year history of intermittent dysuria, was hospitalised on 21 December 2015. Investigations led to a diagnosis of prostate adenocarcinoma. Therefore, he received bicalutamide and goserelin. Eventually, he was diagnosed with nmCRPC. On 03 September 2016, he started receiving docetaxel 75 mg/m2 [route not stated] every 21 days for six cycles with significant improvement. He received docetaxel till 17 December 2016. He also underwent radiotherapy. During treatment, he developed docetaxel-related grade 2 neutropenia [time to reaction onset and outcome not stated]. Additionally, he developed acute rectal haemorrhage of unkown aetiology. By February 2020, at the age of 72 years, his tumour size and lymph node metastases had decreased. Mai L, et al. Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: A case report 803500683 with review of the literature. Translational Andrology and Urology 9: 1428-1436, No. 3, Jun 2020. Available from: URL: http://doi.org/10.21037/tau-20-725
0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 12 Sep 2020 No. 1821
Data Loading...
